Doxorubicin as a Drug Repurposing for Disruption of α-Chymotrypsinogen-A Aggregates

Protein J. 2024 Aug;43(4):842-857. doi: 10.1007/s10930-024-10217-w. Epub 2024 Jul 16.

Abstract

Protein conformation is affected by interaction of several small molecules resulting either stabilization or disruption depending on the nature of the molecules. In our earlier communication, Hg2+ was known to disrupt the native structure of α-Cgn A leading to aggregation (Ansari, N.K., Rais, A. & Naeem, A. Methotrexate for Drug Repurposing as an Anti-Aggregatory Agent to Mercuric Treated α-Chymotrypsinogen-A. Protein J (2024). https://doi.org/10.1007/s10930-024-10187-z ). Accumulation of β-rich aggregates in the living system is found to be linked with copious number of disorders. Here, we have investigated the effect of varying concentration of doxorubicin (DOX) i.e. 0-100 µM on the preformed aggregates of α-Cgn A upon incubation with 120 µM Hg2+. The decrease in the intrinsic fluorescence and enzyme activity with respect to increase in the Hg2+ concentration substantiate the formation of aggregates. The DOX showed the dose dependent decrease in the ThT fluorescence, turbidity and RLS measurements endorsing the dissolution of aggregates which were consistent with red shift in ANS, confirming the breakdown of aggregates. The α-Cgn A has 30% α-helical content which decreases to 3% in presence of Hg2+. DOX increased the α-helicity to 28% confirming its anti-aggregatory potential. The SEM validates the formation of aggregates with Hg2+ and their dissolution upon incubation with the DOX. Hemolysis assay checked the cytotoxicity of α-Cgn A aggregates. Docking revealed that the DOX interacted Lys203, Cys201, Cys136, Ser159, Leu10, Trp207, Val137 and Thr134 of α-Cgn A through hydrophobic interactions and Gly133, Thr135 and Lys202 forms hydrogen bonds.

Keywords: Aggregates; Circular dichroism; Doxorubicin; Drug repositioning; FT-IR spectroscopy; Α-chymotrypsinogen A.

MeSH terms

  • Chymotrypsinogen* / chemistry
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacology
  • Drug Repositioning*
  • Humans
  • Mercury / chemistry
  • Mercury / pharmacology
  • Molecular Docking Simulation
  • Protein Aggregates* / drug effects

Substances

  • Doxorubicin
  • Protein Aggregates
  • Chymotrypsinogen
  • Mercury